BUSINESSFRANCE

DGE DIRECTION GÉNÉRALE DES ENTREPRISES

PARTNERING WITH FRANCE

SWEDEN - Stockholm

September 2016



In collaboration with:

Alsace BioValley HEALTHCARE INNOVATION

ATLANPOLE biotherapies Thinking up tomorrow's medicine

Cancer-Bio-Santé CLUSTER

Eurobiomed

LYONBIOPOLE research • manufacture • market

medicen PARIS REGION innovation for health

NHL CLUSTER NUTRITION · HEALTH · LONGEVITY

SUMMARY

Biotechnologies / French Health clusters

Alsace BioValley HEALTHCARE INNOVATION	**ALSACE BIOVALLEY** - 550 boulevard Gonthier d'Andernach – Parc d'innovation 67400 ILLKIRCH – France Website : http://www.alsace-biovalley.com/en
ATLANPOLE biotherapies Thinking up tomorrow's medicine	**ATLANPOLE BIOTHERAPIES** - Château de la Chanterie - 95, Route de Gachet - BP 90702 44307 NANTES Cedex 3 - France Website : http://www.atlanpolebiotherapies.eu
Cancer-Bio-Santé CLUSTER	**CANCER-BIO-SANTE** - 5 Avenue Irène Joliot-Curie - 31100 TOULOUSE – France Website : http://www.cancerbiosante.fr
Eurobiomed	**EUROBIOMED** - 8, rue Sainte Barbe -13001 Marseille – France Website : http://www.eurobiomed.org
LYONBIOPOLE research • manufacture • market	**LYONBIOPOLE** - 321, avenue Jean-Jaurès - 69007 LYON – France Website : http://lyonbiopole.com/en
medicen PARIS REGION innovation for health	**MEDICEN PARIS REGION** - 3-5 Impasse Reille, 75014 Paris - France Website : www.medicen.org
NHL CLUSTER NUTRITION HEALTH LONGEVITY	**NUTRITION SANTE LONGEVITE** - Parc Eurasanté Ouest - 310 Avenue Eugène Avinée – 59120 LOOS – France Website : http://www.nhl-cluster.com

French industry policy to stimulate economy and strengthen R&D:

A new tool for a most efficient and competitive industry in France was launched since July 2005 when the French Government selected 71 projects as competitiveness clusters.

The competitiveness cluster policy aims to create synergy between companies, public and private research units, academic institutions, in order to establish working relationships which develop an environment of cooperation and promote partnerships within innovative projects. Researchers and business enterprises are mobilized, within a public/private sector partnership, to work on new projects, resulting in innovative advances, economic efficiency and job creation, and which should enable those players involved to attain leading positions in their field. It is a part of French efforts to reach 3% of R&D expenses in the GDP, according to the European "Lisbon Strategy".

The competitiveness clusters are addressing the technological sectors with higher impact on French economy: information and communication technologies, energy and environment, health related technologies, biotechnologies, aeronautics and transportation, food industry.

A competitiveness cluster is an organization which brings together the best players in their field, small or large, where each participant can benefit from access to the following:

- Leading players in their field.
- Top level researchers.
- Qualified personnel.
- Public financial support to encourage innovative projects, in the best possible conditions.

Moreover, due to their international vocation, the competitiveness clusters facilitate:

- the setting up of foreign business enterprises who benefit from this technological environment;
- the creation of international research teams;
- the development of technological partnerships with companies and research centers of foreign clusters.

The success of this innovative industrial and country planning policy is contributing to the favourable orientation of French economic indicators: improvement of the economic growth, new positive level of manufacturing investments and rise of R&D expenditure.

The French competitiveness clusters are under the supervision of the Regional Directorates for Enterprises from the Ministry of Economy, Industry and Digital Affairs.

Website: www.competitivite.gouv.fr

AXENIS

AXENIS
28, rue du Dr Roux
75015 Paris
France

www.axenis.fr

Erwan CORCUFF
CEO

☎ +33 (0)1 45 68 80 74
+33 (0) 6 81 33 49 03
✉ erwan.corcuff@axenis.fr

Affiliated to the following cluster:

medicen PARIS REGION innovation for health

Pre-clinical models for innovative medicine

COMPANY:

AXENIS, a spin-off of the Institut Pasteur, is a French contract research organization generating, exploiting and developing mouse models humanized for molecular and cellular components of the immune system. The model portfolio of AXENIS is based on the proprietary immunodeficient BRGS ***(BALB/c Rag2^{tm1Fwa} IL-2Rγc^{tm1Cgn} SIRPa^{NOD})*** mouse model, which is particularly permissive to the long-term establishment of a variety of human xenografts, including human tumor cells. When BRGS mice are transplanted with human hematopoietic stem and progenitor cells, such as umbilical cord blood CD34^{+}cells, the resulting 'Human Immune System' (HIS) mice support the development and maintenance of a large diversity of human hematopoietic cell subsets, such as B cells, T cells (including CD4^{+}Treg cells), NK cells, and myeloid cells such as conventional dendritic cells (cDCs), plasmacytoid dendritic cells (pDCs) and monocytes/macrophages. This myeloid compartment can be boosted with a simple exogenous Flt3-ligand treatment in BRGS mice lacking the corresponding mouse receptor (Flk2/Flt3). The boost of human dendritic cells accumulation and maturation in this novel BRGSF **(*BALB/c Rag2^{tm1Fwa} IL-2Rγc^{tm1Cgn} SIRPa^{NOD} Flk2 ^{tm1Irl}*** **)** HIS mouse model strongly potentiates human B and T cell functionality, resulting in unprecedented levels of human, antigen-specific immune responses. These optimized humanized mouse models introduce a variety of new solutions for academia, biotech companies and biopharmaceutical industries that are looking for innovative in vivo models for immuno-oncology, inflammation, host-pathogen interactions and preclinical validation of biotherapeutics, e.g. vaccines, monoclonal antibodies, cellular products or small molecules targeting hematopoietic cells. Furthermore, HIS mice represent an attractive preclinical platform for the evaluation of therapeutics requiring the simultaneous presence of both human tumor and human effector cells, such as immune checkpoint inhibitors, bispecific antibodies or CAR-T cells. As such, HIS mice can therefore be used both as a standardized model or in personalized medicine approaches.

TECHNOLOGY:

Humanized mice as a breakthrough in human biomedical research

Mice 'humanized for the immune system' (HIS mice) are under development since the late 80's, and led to major technological discoveries in the fields of immuno-deficient mice and human hematopoietic stem cells – the two key components required to generate such models. In brief, HIS mice are generated by transplanting human hematopoietic cells (preferably human hematopoietic stem cells) into immuno-deficient mouse hosts (preferably newborns) after conditioning (e.g. full-body irradiation), generating what could be considered as a 'live test tube' giving access to human immune cells in an *in vivo* context



OBJECTIVES:

AXENIS is looking for new customers from Swedish market to provide them the most advanced humanized mouse models as preclinical tools in immuno-oncology field.
This includes standard testing in HIS mice available 'from the shelf', services in application-specific models or custom-made models constructed to meet customer needs.

BANOOK GROUP - CARDIABASE

One of the few established international providers capable of supplying cardiac safety, central imaging and endpoint adjudication services to pharmaceutical, medical device and biotech companies, CROs and nonprofit organizations

COMPANY:

Banook Group's mission is to help its clients **to assess the cardiac safety of their new drug**, using qualitative, reliable and innovative solutions in early to late stage clinical trials and ultimately to bring new solutions to the market for the benefit of patients worldwide.

Its medical and regulatory expertise, quality-driven approach and team availability make the Banook Group a key player for clinical trial services.

Since its establishment, Banook group performed over **1 million ECGs analyses and 35,000 patient files adjudicated for over 750 clinical projects** (including 300 intense ECGs trials)

Founded in 1999, Banook Group is a non-listed family company. Financially stable and strong, the group operates on an international scale, maintaining offices at its headquarters in Nancy (France) and in Montreal (Canada).

TECHNOLOGY:

Banook group offers new **early cardiac safety assessment service** as a response to the changes to ICH E14 regulation made in December 2015.

The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) indicated that, for the mandatory QT study, manufacturers may now choose pharmacokinetic and pharmacodynamic (PK/PD) ECG modeling as an acceptable alternative to by-time-point analysis, as the primary basis for decisions.

In order to take full advantage of these regulatory changes, **Banook Group has developed an optimized approach that enables pharmaceutical laboratories to file as soon as possible for a QT waiver in early-stage candidate drug development.** Obtaining a QT Waiver from regulatory bodies means that subsequent clinical trials are not subject to a recommendation regulating cardiovascular monitoring and thus avoiding intensive and costly late assessments.

OBJECTIVES : Collaborations and Clients

Banook group is looking for new partners to extend operational capacities and its presence in new markets. In return, Banook's partners will benefit from its experience in terms of **scientific, methodological and operational support.** They will also be able to offer their clients an additional service that complements their current offering.

BANOOK GROUP - CARDIABASE
78 Avenue du 20ème Corps
Villa - Alsacienne
54000 NANCY
France

www.banookgroup.com

Alexandre DURAND-SALMON
Chief Operating Officer
☎ + 33 (0)3 83 39 43 18
+33 (0)6 80 46 09 07
✉ alexandre.durand-salmon@banookgroup.com

Affiliated to the following cluster:

BERTIN PHARMA

BERTIN PHARMA
Parc d'activités du Pas du Lac
10 bis, avenue Ampère
78180 Montigny-le-Bretonneux
France

www.bertinpharma.com

Cécile OLIVARIUS
Business Development Manager

☎ + 33 (0)1 39 30 60 10
+33 (0)6 80 57 62 48
✉
cecile.olivarius@bertinpharma.com

From screening to manufacturing
Bertin Pharma

Affiliated to the following cluster:

medicen PARIS REGION | innovation for health

bertin pharma
care. innovate. deliver.

Research Solution Provider—Biologics development or characterization.

COMPANY:

Bertin Pharma, leading company on the European pharmaceutical, cosmetic and nutraceutical market is your partner in preclinical and clinical studies, pharmaceutical development & clinical supplies.
Bertin Pharma can assist you with its comprehensive and integrated offer of products and services throughout the drug development value chain. A dedicated project manager will make available Bertin Pharma's expertise and good professional practice facilities to shape the best scenario to make your drug a success.
Established in the Paris area, in the Centre region and nearby Bordeaux, Bertin Pharma benefits from a loyal and prestigious client base: Big & Mid Pharma, biotech Companies and also public research laboratories. Bertin Pharma is involved in the technological progress through its internal and collaborative R&D activities, in particular with the French Atomic Energy Commission (CEA) and the Institute of Industrial Pharmacy of Bordeaux.

The Company is also very active in the R&D sphere: it serves on the board of the competitiveness cluster and as President of the French Association of Innovation and Services Societies for Life Sciences (AFSSI), being one of its co-founder.

Full range capabilities in Life Science Tools

⇒ A wide range of the most relevant state-of-the-art products in various investigation fields including Inflammation, Oxidative injury, Endocrinology, Diabetes, Obesity, Hypertension, Psychopharmacology, Cancer, Asthma, Prion diseases
⇒ Biomarkers assays (several technologies)
⇒ Proteins & Chemical entities

A comprehensive offer in pharmaceutical development

⇒ Development solutions with the widest range of technologies (new chemical entities & biologics)
⇒ products including highly potent drugs
⇒ Pre-formulation to scale up and registration
⇒ Clinical batches supply chain

Cutting-edge methods to assess NCEs & biologics ADME

⇒ Full & comprehensive range of drug metabolism and pharmacokinetic (ADME) studies in support of drug/biotech candidate selection to regulatory submission
⇒ Both standard study designs and innovative approaches
⇒ early in vitro & in vivo ADME;
⇒ No-clinical & clinical PK & metabolism;
⇒ Production of Phase I & II metabolites (biotransformation / biocatalysis)
⇒ Biotech focus topics such as ADA assessment.

Translational medicine & immuno-pharmacology

⇒ To evidence the efficacy & safety of drugs, vaccines, adjuvant, immune therapies, gene therapies, neutraceutics, cosmetics; to determine their mode of action
⇒ Immuno-pharmacology- Immunotoxicology;
⇒ Antimicrobial & antiviral pharmacology being co-founder of the Research Center for Infectious Disease Models and Innovative Therapies (IDMIT);
⇒ Viral & prion bio safety;
⇒ Biobanking incl. infectious samples.

OBJECTIVES :

Bertin Pharma is looking for new European partners and customers searching for cutting edge technologies and innovative solutions especially in the field of biologics development or characterization.

CELLVAX PHARMA

Preclinical studies in Cancer and Osteoarthritis (OA) fields.

COMPANY :

Cellvax, founded in 2001, is a French SME which provides complete preclinical innovating drug validation studies both *in vitro* and *in vivo* (rodents and non-rodents) allowing to accelerate the drug development process for unmet needs related to severe human diseases, mainly in Cancer and Osteoarthritis (OA) fields. Cellvax was created by a motivated and complementary team consisting of scientists and experts in these fields. By offering its know-how and its capacity of innovation, Cellvax is willing to collaborate with public and private laboratories. Cellvax's expertise is based on its know-how in the field of molecule biology, cellular biology, and original *in vitro* and *in vivo* models. These services can be offered to all laboratories involving in anti-cancer and anti-OA drug development process. These proposed services adapt to the validation and development of drug candidates and fully validated such as sub-cutaneous and orthotopic tumors models in animals; *in vitro* and *in vivo* angiogenesis models; an original "Nodule" system, *in vivo* imaging, bio-distribution, pharmacokinetics, toxicity, spontaneous and induced animal models for OA, etc. Cellvax is always ready to obey market evolution and to satisfy its customers' specific needs all over the world. Cellvax is strongly willing to develop and enhance its national and international collaboration with public laboratories, biotechnological companies and pharmaceutical companies. In order to expand our offers, Cellvax has moved to "Ecole Nationale Vétérinaire de Maisons Alfort". Cellvax is able to provide a number of new services in large animals, *in vivo* imaging, MRI, Scanner, Scintigraphy radio-labeled compounds, etc. Thus, Cellvax is able to provide the services not only in small animals, but also in large animals in a more efficient way. Since March 2015, we have settled in the biotech Park, the former Sanofi industrial site, Biocitech to further provide and guarantee a better quality of our services.

Furthermore, Cellvax is actively involved in different European large collaborative projects. Cellvax has successfully launched its 1st EUREKA project in 2007 in cancer field. In 2011, Cellvax has successfully obtained a 2nd FP-7 grant. In 2015, an "eurostars" program for the treatment of triple negative Breast cancer, and two "EURONANOMED" projects in 2016 in cancer and OA fields. These large European collaborative projects not only allow for Cellvax to develop its R&D activity, but also allow increasing its visibility within European community, thus greatly beneficial for Cellvax's development.

In 2016, Cellvax has concluded a strong partnership with a French national organisation, BIOBANQUES, "Infrastructure BIOBANQUES-Inserm US13" inside the hospital "Hôpital de la Pitié-Salpêtrière" in Paris in order to further enhance its capacity to provide different *in vivo* drug validation models.

TECHNOLOGY :

Cellvax, founded in 2001, is a fast-growing technology-driven pre-clinical service company focalizing on oncology and Osteoarthritis (OA). Today, Cellvax directly employs and through R&D collaborations motivated and differently skilled scientists and engineers, working in interdisciplinary teams on several innovative products. Since its foundation, Cellvax has significantly progressed as a service company, especially in different cancer and OA models in animals, angiogenesis models *in vitro* and *in vivo*. We have concluded numerous contracts with different companies in France, in Europe and in the world. Here is a brief summary of our different models: 1). Anti-proliferative tests *in vitro*; 2). Original Nodule model *in vitro*; 3). Toxicity in animal models (both rodent and non-rodent); 4). Subcutaneous animal cancer models; 5). Angiogenic tests *in vitro* & *in vivo*; 6). Tumoral invasion tests *in vitro*; 7). Tumoral invasion tests *in vivo*; 8). Orthotopic tumor models; 9). Syngeneic tumor models in animals; 10). Original drug-resistant tumor models *in vitro* & *in vivo*; 11). *In vivo* imaging in alive animals (PET and Bioluminescence); 12). Primary tumor cells; 13). More relevant tumor models: 13A. Direct implantation of human tumor biopsies in mice 13B. Non-rodent cancer models, spontaneous tumors; 14). Bio-distribution and PK studies *in vivo* (both rodent and non-rodent); 15). Spontaneous and induced OA models in animals; 16). Other specific models; 17). Complete histological analysis and/or with experts' interpretations; 18). Mechanisms od actions studies, ELISA, FACS, Biomarkers, etc.; 19). Diabetic models; 20). Other specific studies upon request.

OBJECTIVES :

By participating in this event, Cellvax primarily aims to conduct preclinical validation studies (in vitro screening tests, anti-tumor and anti-OA studies, in vivo toxicology studies, PK/Bio-distribution studies, etc.). These designed would greatly speed up drug development process. Thus, drug developments costs will be decreased, the time line will be shortened, and better and more efficient drugs will be developed in shorter time. Cellvax is looking for establishing partnerships or acts as a service provider (fees for services) with drug discovery companies.

CELLVAX PHARMA
Parc BIOCITECH
102, Avenue Gaston Roussel
Ile de France
93230, Romainville
France

www.cellvax-pharma.com

WEI Ming
CEO

☎ + 33 (0) 9 52 30 26 20
+33 (0) 6 71 43 47 51
✉ ming@cellvax-pharma.com

Affiliated to the following cluster:

CLEVEXEL PHARMA

CLEVEXEL Pharma
19 Avenue du Prof. Cadiot
94700 Maison Alfort
France

www.clevexelpharma.com

Laurent BENEL
CSO

☎+ 33 (0)01 79 84 19 28
+33 (0)6 85 04 04 92
✉ laurent.benel@clevexel.com

Affiliated to the following cluster:

CNS

COMPANY :

Founded in 2013, CleveXel Pharma has a team of 38 scientists that select molecules with substantial potential, optimize them and develop them through to proof of concept in humans with the aim of licensing them out to major players in the pharmaceutical industry.

CleveXel Pharma is an expert in diseases of the central nervous system with a unique positioning in France. Specializing in Parkinson's disease, the Company is currently developing two first-in-class drug candidates that use innovative therapeutic approaches to overcome the limitations of current drug treatments and thus improve the quality of life of patients with Parkinson's.

- A spin-off from the Cephalon France laboratory (TEVA Group)
- Historical know-how in drug development for diseases of the Central Nervous System (CNS)
- A solid positioning in the field of Parkinson's disease with 2 first-in-class products, one of which is already in Phase II
- A relevant out-licensing model of innovative drugs for pharmaceutical laboratories
- Substantial involvement and commitment of top management, which owns 95% of the share capital

OBJECTIVES :

Collaborations and Clients

- CleveXel Pharma is looking for new partnership opportunities, with promising projects in the field of CNS.
- We are continuously evaluating collaboration opportunities for our whole portfolio, but we currently focus on **:**

⇒ A licensing partner or a co-developer for our mucitis preventive treatment, CVXL-0095

⇒ A licensing partner or a co-developer for our SYK/JAK drug candidate, CVXL-0074

Innovating to Treat Parkinson's Disease Patients

EUKARYS

Active, well tolerated and safe non-viral gene therapies for complex multifactorial human disorders, based on its proprietary expression system C3P3.

COMPANY:

The C3P3 expression system: is the core technology of Eukaryÿs and is used for all applications described hereinafter. This proprietary synthetic system allows the autonomous production of messenger RNA and/or inhibitory RNA sequences in the cytoplasm of eukaryotic cells. This processive system can be used in virtually any type of eukaryotic cells (micro-organisms, including yeasts and protozoa, plants and animals including mammals). Yet, the C3P3 system can be used either transiently or stably for virtually all in cellulo (i.e. cultured cells) or in vivo (i.e. ubiquitous or targeted expression) therapeutic or experimental applications.

Non-viral C3P3-based gene therapy and EUK01: is the core business development of Eukaryÿs. In brief, Eukaryÿs develops synthetic non-viral gene therapies for the treatment of common multifactorial disorders based on its C3P3 technology and other ongoing developments. In contrast to the "classical" viral gene therapy, Eukaryÿs therapeutic approach is aiming to treat common and severe multifactorial diseases requiring acting on several cellular factors with good safety margins. EUK01, the first non-viral gene therapy based on the C3P3 technology, is a designed to treat a severe multifactorial liver condition. This program entered into animal preclinical development with promising results. Regulatory preclinical studies are planned in 2018 and phase I/IIa studies in 2019-2020. Further therapeutic developments will be launched soon, which will be facilitated by the fact that the production process of any C3P3-based gene therapy products remains virtually the same.

Stable C3P3 cell lines: Eukaryÿs is willing to generate and market stable GMP-compliant cell lines (CHO-K1 and HEK-293) that constitutively express the latest version of the C3P3 enzyme. The C3P3 system is featured by much higher production yields than the existing competition.

Other applications of the C3P3 system: other uses of the C3P3 system (cell therapy, bioproduction using non-mammalian vegetal or yeast cells, bioassays, animal or vegetal transgenics, are open for licensing and/or partnerships.

OBJECTIVES:

Non-viral gene therapy and EUK01: partnerships with Biotech, Pharma and academic groups to develop other products.

Stable C3P3 cell lines: partnerships with Biotech or Pharma only, in order to generate and market stable cell lines (CHO-K1 and HEK-293) that constitutively express the second generation of the C3P3 enzyme.

Other applications of the C3P3 system: licensing out and/or partnership with Biotech, Pharma and academic groups.

EUKARYS
3 - 4 rue Pierre Fontaine
91058 EVRY
France

www.eukarys.com

Philippe JAIS
CEO, CSO

+33 (0)6 72 81 50 48
philippe.jais@eukarys.com

Affiliated to the following cluster:

FIRALIS

FIRALIS
35 rue du Fort
68330 Huningue
France

www.firalis.com

Tony YAACOUB
Chief Business Officer

☎ + 33 (0) 3 89 911 324
+33 (0)6 37 45 71 45
✉ tony.yaacoub@firalis.com

Affiliated to the following cluster:

Alsace BioValley
HEALTHCARE INNOVATION

Firalis, a global actor in personalized medicine creating novel values via biomarkers discovery

COMPANY :

Firalis is a biotechnology company, developing **biomarkers** (BM), particularly in the **Cardiovascular, Inflammatory and Neurology fields**, for pre-clinical and clinical applications such as:

- BM-based detection of potential toxic effects of drugs & drug-candidates
- Identification of patients for whom drug treatment may be toxic
- Selection of responding patients to a given treatment
- Diagnosis of cardiovascular disorders with inflammatory components
- Bio-analysis of preclinical and clinical samples in an accredited environment (ISO 17025 and GCLP compliant), with technologies such as Luminex BioPlex200, MesoScale Discovery, Singulex Erenna and Protein Simple Ella
- Profiling of more than 2256 miRNAs and 2560 mRNAs oncogenes on low sample volume with the HTG EdgeSeq platform
- NGS services including whole genome sequencing, transcriptome and exome analysis and targeted sequencing with Illumina NextSeq 500
- Multi-color and multi-parameter high-throughput Navios Flow Cytometry platform:
  - ⇒ immunophenotyping of preclinical and clinical samples and biomarker discovery
  - ⇒ monitoring of pharmacodynamics on target cells in response to treatment and compound screening using cell physiology signatures
- Assay development and validation on various platforms (ISO 13485 certified facilities)
- Development of critical reagents (antibodies & recombinant standard materials)
- GMP manufacturing of assay kits and assay kit components (ISO 13485 and ISO 9001)
- Biobanking and sample repository services (NF S 96-900) supported by LIMS
- Data analysis using multi-parametric statistics and development of predictive models
- Support of regulatory activities related to biomarker qualification with Health Authorities (FDA/EMA)

OBJECTIVES:

Identify business opportunities with new clients, meet new partners

GENOPOLE

Promoting the creation and development of life sciences companies

Genopole is France's leading biocluster with a special focus on life sciences.

Genopole is built upon the model of American and European campuses and unites nnovative high-tech life sciences companies, public and private research and higher education facilities at a single site in Evry/ Corbeil-Essonnes, just south of Paris.
Genopole is soundly engaged to improve health and well being of all citizens by supporting highly innovative projects and start-ups. Since its creation in 1998, thebiocluster has been growing steadily and is currently home to 19 academic labs, 82biotech companies and 25 shared-use facilities.
Field sectors are health therapeutics, diagnostics, medical devices, e-Health, scientific instrumentation, biomanufacturing and pharmaceuticals services… but also, industrial biotech, food/agritech and environment sectors.
Genopole is one of the top European bioclusters and employs over 2,300 people.
Key figures:
- 5 publicly traded companies
- 503 M€ in funds raised by companies
- 41 products from the regulatory preclinical phase to market lunch,
- several international firms as New England Biolabs, Pharming, Santen SAS or Arianne Clinical.

<u>OBJECTIVES</u> : individual follow-up of projects and companies :

Genopole' mission is to promote the creation of high-tech companies and provide business support from the first day (the genesis of the business idea) through to the successive funding rounds. A team of 8 dedicated project and business Managers is here to help create, setup and grow your project or biotech company. The goals are to transform the results of life science research into drugs or industrial products, build a truly world-class biocluster and contribute to the emergence of innovating biotech companies.
The Genopole enterprises team is made up of experienced project managers with complementary backgrounds in science and business. The individual fellow-up covers all the operational phases in business creation and development.
Genopole works closely with other business support organizations and the financial community to provide budding or experienced entrepreneurs with scientific, managerial, logistic and financial assistance.
Genopole will help the entrepreneurs :
1. to transform their ideas into market-validated companies including fundraising, business development, industrial alliances and turnover generation
2. to promote the strategic and financial development of the company on the international level
3. to operate successfully with in- and out-licensing
4. to facilitate the access to high level technical platforms and scientific knowhow of excellence
5. to maturate products development strategy, and commercialization
6. to participate to on-site networking events with monthly business clubs for promoting dialogue on key corporate issues.

In addition Genopole has been selected to be part of **The French Tech Ticket program** for international start ups (http://www.frenchtechticket.com/)

The laureates of this program will be individually followed-up for every phase of the maturation of its project or start-ups

Our goal is to facilitate the integration of project, start up and companies in the innovation ecosystems.

GENOPOLE
Genopole Campus 1
5 rue Henri Auguste-Desbruères -
91030 Evry Cedex
France

www.genopole.fr
www.genopole.fr/?lang=en#.Vz3ocWM2b_s

Laurent PEPIN
International Project Manager

☎ + 33 (0) 1 60 87 83 15
+33 (0) 6 08 88 38 74
✉ laurent.pepin@genopole.fr

Affiliated to the following cluster:

GLOBAL CARE INITIATIVE

GLOBAL CARE Initiative
Institut Pasteur, 28 rue du Dr Roux
75015 Paris
France

www.globalcare-initiative.com

Bertand COULOMB
Head of Development Europe

☎ + 33 (0) 1 45 68 88 61
+33 (0) 6 77 94 17 93
✉ bertrand.coulomb@globalcare-initiative.com

Affiliated to the following cluster:

medicen PARIS REGION innovation for health

GLOBAL CARE Initiative
The Global Partnership Research Initiative of the Carnot Human Health Institutes

GLOBAL CARE Initiative is a consortium of five leading non-profit French research institutes seeking new partners for R&D projects (basic to clinical research) in:

- Cancer
- Lymphoma
- CNS diseases
- Infectious diseases
- Visual and auditive impairment

COMPANY :

GLOBAL CARE Initiative is a consortium of five leading non-profit French research Carnot institutes:

- **Pasteur MI**, a component of Institut Pasteur (infectious diseases),
- **Curie-Cancer**, a component of Institut Curie (cancers),
- **ICM**(1) (CNS diseases),
- **Voir et Entendre** (2) (vision / ophthalmology and audition diseases and rehabilitation) and
- **CALYM** (3) (lymphoma).

They represent the very best of French research in human health and include a legacy of 15 Nobel Prizes.

GLOBAL CARE Initiative was founded in 2012. It has received funding from the French government, through the program Investments for the Future.

The consortium functions as a **one-stop-shop for life science companies and research organizations that seek R&D partnerships**. They can be tailored to work at any stage - from basic research to the late clinical phases. GLOBAL CARE Initiative combines strong skillsets, recognized IP and unique technology platforms. The consortium is widely acknowledged for its extensive experience of partnerships with major pharmaceutical, biotech and medtech companies. It has lead innovative projects across diverse fields, including therapeutics, biomarkers, vaccines, diagnostic and imaging.

(1) Institut du Cerveau et de la Moelle Epiniere - Brain and Spine Institute

(2) Seeing and Hearing Institute

(3) Consortium for the acceleration of innovation and its transfer to the field of Lymphoma

About the Carnot Institutes: The Carnot institutes network (http://www.institutscarnot. eu/en) gathers 34 major French research structures dedicated to fostering companies' innovation. The Carnot institutes generate 50% of academia/industry partnerships in France and are supported by the French Government to develop a quality-guided approach for a better and more innovative applied research with companies.

OBJECTIVES :

Seeking new partners for R&D projects.

HISTALIM

Discover HISTALIM, a service provider company in histology, immunohistochemistry, in situ hybridization and image analysis for ten years.

COMPANY: :

Histalim is a service provider company in histology, immunohistochemistry (IHC), in situ hybridization (ISH), and image analysis. Our laboratory located in Montpellier was founded in 2005. This positioning shows our willingness to meet the increasing demand to design, develop, and validate protocols based on standard and/or innovative techniques.

Our specialized services take part in research and development projects for pharmaceuticals products, medical devices, and diagnostic tools… and in other domains like dermo-cosmetic, ecotoxicity, food industry… We are particularly engaged in the development of new therapies in the domains of oncology and chronic diseases i.e. therapeutic antibody, and new generation diagnostic tools i.e. morphologic biomarkers. Histalim positions its strategic growth specifically in the development of therapeutic antibodies issues.

Our activities are conformed to Good Laboratory Practices (GLP) and our laboratory is authorized to perform studies with human tissue samples. Histalim can also offer to perform in-house research and development projects. This particularity allows us to provide some customized services to our customers, with innovative technologies. Therefore we can provide a large range of expert services like Tissue Cross Reactivity (TCR) studies, Tissue MicroArray

(TMA), and Fluorescent ISH (FISH)…

TECHNOLOGY :

Histalim is equipped with labelling automatons (LEICA BOND III, DAKO Autostainer, ROCHE Ventana, BenchMark, Discovery) for immunohistochemistry and in situ hybridization to optimize its routine production. The company is also equipped with new devices to diversify its scope of services (Tissue clearing with CLARITY™ Tissue Clearing System, cutting in resin for histology for implantable medical devices…).

Moreover, our new premises are equipped with optical fiber which allows Histalim to speed up its works in digital pathology analyses

(Telediagnostic, peer-reviewing…).

Finally, our laboratory is equipped with a histological slide scanner platform (HAMAMATSU Nanozoomer) which allows us to work with virtual high resolution images and provides some customized image analysis tools. This new technology offers the opportunity to perform digital pathology studies with our pathologists' network.

OBJECTIVES:

Collaborations and customers

HISTALIM is looking for academic research institute, biotechnology lab, CRO (Contract Research Organisation) and startup in health and biotechnology sectors for technical cooperation agreement, services agreement and research cooperation agreement.

For research cooperation agreement, we have several successfully experiences in collaborative projects. We are also interested in participate in european projects as member of a consortium for example.

HISTALIM
126, rue Emile BAUDOT
34000 MONTPELLIER
France

www.histalim.com

Jean-Philippe COTON
CEO
☎ + 33 (0)4 67 712 765
✉ jpcoton@histalim.com

Affiliated to the following cluster:

Eurobiomed

INOVOTION

INOVOTION
Biopolis, 5 Avenue du Grand Sablon
38700 La Tronche
France

www.inovotion.com

Arnaud PEYRONNIER

Business Development Manager
☎+ 33 (0)4 76 54 95 12
+33 (0)7 68 05 70 53
✉ arnaud.peyronnier@inovotion.com

Affiliated to the following cluster:

LYONBIOPOLE
research • manufacture • market

inovotion
WHICH MOLECULE WILL STAND OUT

INOVOTION offers a unique in vivo oncology efficacy and toxicity assay.

COMPANY:

Our **Fast**, **Sensitive**, **Reliable** and **Affordable** assay will save you time and money, to give you a clear competitive advantage**.**

This cutting-edge technology, based on chick embryos, provides early analysis of your drug candidates, before the classical preclinical stages. By eliminating low-value molecules early, INOVOTION accelerates your drug discovery process, increases your R&D productivity and reduces its costs.

INOVOTION assays evaluate:

⇒ EFFICACY and early TOXICITY of your anticancer treatments on more than 10 types of cancers

⇒ TARGET VALIDATION in oncology

⇒ MULTI-CANCER SCREENING for your candidate treatments

These accessible efficacy and toxicity assays open new perspectives of screening for chemists and biologists from academic labs, biotech and pharma companies to develop new molecules, while staying within their budget.

Our innovative technology allows rapid Go/No Go decisions and thanks to its capacities of **multi-cancer screening**, you don't miss any valuable molecules.

TECHNOLOGY:

Oncology Efficacy Studies

In vivo impact of drug candidates on: tumoral proliferation, metastasis invasion and mortality

Target Validation

In vivo evaluation if a specific target is involved on tumoral proliferation and/or metastases invasion

Toxicity Evaluation

Monitoring of drug impacts on different toxicity parameters: mortality rate, head formation, body development, limb evolution, skin aspect and extra embryonic structures

Multi-Cancer Screening

Test your compound on 10 cancers! Don't miss any valuable molecules. Find the right positioning of your molecule or repositioning a non-clinical or clinical compound on the best cancer.

OBJECTIVES:

1) Discussion with academics, biotech and pharma looking for in vivo proof of concept in oncology and early toxicity.

2) Interesting by partnerships and collaborations

LEADS TO DEVELOPMENT

Provides preclinical development and regulatory support to allow partners to obtain clinical trial authorisation more rapidly and cost effectively. Our expertise covers therapeutic products, medical devices and diagnostic products.

COMPANY:

We offer consultancy, regulatory support and operational project management services to our clients in order to help them bridge the gap between therapeutic lead identification and clinical development.

We provide regulatory support including:

- Determining the optimal regulatory strategy
- Designing the development plan
- Obtaining scientific advice from regulatory authorities
- Writing clinical trial applications
- Liaison with regulatory authorities

Our operational project management services include technical support and coordination of:

- *In vivo* pharmacology
- Production & formulation (CMC)
- Analytical method development and stability testing
- Toxicology & safety pharmacology
- Bioanalytical method development

We offer a personal service carefully tailored to our customers' needs that maintains the transparency, flexibility and availability associated with an internal team. Our thorough understanding of the biotechnology sector also allows us to offer a range of business and strategic advice and services (including due diligence) to investors, academic groups, technology transfer offices, biotechnology and pharmaceutical companies. We provide the expertise required to assess project potential, design development strategies and deliver effective project advancement in a manner that minimises risk and increases project value.

OBJECTIVES:

Our objective during the mission is to identify new collaborations either with biotech or pharmaceutical companies that require development and/or regulatory support and to meet with service providers that are able to support *in vivo* pharmacology, toxicology, formulation and/or production aspects of drug development. We are also interested in undertaking translational research within European or national funded collaborative programmes (H2020 etc).

LEADS TO DEVELOPMENT (L2D)
166 boulevard du Montparnasse
75014 PARIS
France

www.leadstodevelopment.co

Jonathan KEARSEY
Director
☎ + 33 (0)1 82 28 53 70
+33 (0) 6 89 34 57 32
✉
jkearsey@leadstodevelopment.com

Affiliated to the following cluster:

PORSOLT

PORSOLT
ZA de Glatigné
53 940 Le Genest Saint Isle
France

www.porsolt.com
www.fluofarma.com

Sébastien BRECHE
Associate Director Business Development

☎ +33 (0)2 43 69 36 07

+33 (0)6 84 77 41 46

✉ sbreche@porsolt.com

Affiliated to the following cluster:

ATLANPOLE biotherapies
Thinking up tomorrow's medicine

Scientist-to-Scientist, Contrat Research in Preclinical Pharmacology

COMPANY:

Porsolt, a long established, AAALAC accredited and fully GLP compliant, preclinical CRO, has been providing screening, efficacy evaluation and safety pharmacology services for over 30 years, covering the drug development process from early screening thru regulatory submission.

TECHNOLOGY :

Porsolt provides **physiopathological models in multiples species, customized procedures, and tailored solutions,** (including in vitro assays and drug formulation analysis and bioanalytical services), for **psychiatric and neurological disorders, pain, cardiac and vascular diseases, metabolic and eating disorders, and dermatology.**

Porsolt recently acquired Fluofarma, a preclinical in vitro CRO, expanding our capabilities to now provide high throughput screening, high content analysis, and high content histology services, allowing us to cover more of the drug development process and further meet the needs of our clients.

OBJECTIVES :

Porsolt is looking for expand existing relationships with companies and to establish new relationships

PX'THERAPEUTICS

A CDMO (Contract and Development Manufacturing Organization), specialized in the development and production of recombinant proteins including mAbs. Our aim is to add value to our customer's drug candidates for facilitating their entry into clinical phases.

COMPANY:

PX'Therapeutics, subsidiary of Aguettant group, provides integrated recombinant protein (including mAb) development and manufacturing services.

Our mission is to help our customers to choose and optimize their candidate for higher developability, to develop efficient production process and to transfer this process in GMP in order to deliver up to hundreds grams of protein, for use in clinical trials.

PX'Therapeutics has been extensively involved in the discovery, development and manufacturing of drug targets, vaccines, ancillary materials, cell-based products, therapeutic proteins and monoclonal antibodies with over 800 projects performed during the last 15 years through 230 customers (North America, Europe, Asia).

TECHNOLOGY:

We offer custom development programs which may include, depending on customer needs:

- Sequence optimization, by protein engineering, mAb chimerization & humanization

- Feasibility studies for the production of recombinant proteins (including mAb and antibody fragments) in bacteria, mammalian cells, yeast, insect cells (mg to 100 g)

- Cell line development

- Development of robust and scalable process, (USP in batch or fed-batch)

- Development of specific analytical methods for in process controls & product characterization. Proprietary technology for the quantification of protein using mass spectrometry through our subsidiary Promise Advanced Proteomics (www.promise-proteomics.com)

- Small-mid scale GMP manufacturing (50L scale fermentation volume for bacteria and yeast & 250L for mammalian cells)

OBJECTIVES :

Collaborations and clients:

PX'Therapeutics is looking for new customers to support them in their biotherapeutic development by adding value to their candidates, facilitating their entry into clinical phases.

Our business model is mainly based on fee-for-services but we are open to discuss any specific demand. We are also involved in French & European R&D collaborative programs

PX'THERAPEUTICS
7, parvis Louis Néel – CS 20050
Minatec / BHT - 52 A
38040 Grenoble Cedex 9
France

www.px-therapeutics.com/

Delphine BOULANGER
Business Development Manager

☎ + 33 (0)4 38 02 36 65
+33 (0)6 18 45 33 54
✉ delphine.boulanger@px-therapeutics.com

Affiliated to the following cluster:

LYONBIOPOLE
research • manufacture • market

VOUTE SAS

VOUTE SAS
Le bruyère 2000,
650 Avenue Henri Becquerel
34000 MONTPELLIER
France

www.clestclinical.com

Ouafae JARRI
Business Developer

☎ +33 (0)4 67 42 29 09
+33 (0)71 73 33 95

✉ ojarri@voute-sas.fr



Affiliated to the following cluster:

Eurobiomed Biocluster Méditerranée

Discover C-LEST patient, the must have payment solution for clinical trial

COMPANY :

Our first idea is that patients who participate in a clinical trial can be reimbursed for expenses incurred. Those costs must be defrayed by the sponsor without knowing the identity of the patient (GCP DIR2001/20/CE). Only a third party is authorized to secure the patient anonymity.

OUR CONVICTION:
IT IS POSSIBLE TO REDUCE THE COST OF CLINICAL TRIALS AND ALLOWING TEAMS TO BE MORE EFFICIENT.

OUR ETHIC:
CREATE NEW ROUTES FOCUSED ON PATIENT RIGHTS

IT IS IN THIS SPIRIT THAT WE DEVELOPED AN APPLICATION & PROCESS FOR CLINICAL RESEARCH SO THAT TOMORROW THEY ARE THE STANDARD.

Voute company developed an application allowing the management of patient expenses reimbursements during clinical trials.

C-Lest patient application is in compliance with 3 regulations involved in this complex process: patient anonymity, traceability, and regulation about payment on behalf of third parties. C-LEST PATIENT is the only compliant solution in Europe.

Besides ensuring compliance, you will reap many benefits using our solution

C-LEST (SaaS) for all studies in Europe (SEPA area) and in United States + Canada+ South Africa as 10 currencies are available.

Thanks to C-lest Patient, you will eliminate the risk of misconduct, simplifying the validation circuit till the payment, costs will be optimized, you will save time and money.

Voute is currently developing 2 other modules allowing the management and the payment of investigators fees as well as additional costs.

Voute is also involved in another research projects.

OBJECTIVES :

COLLABORATIONS ANS CLIENTS. Voute is looking for new partners for c-lest patient and other future modules.

MEDICEN PARIS REGION

MEDICEN PARIS REGION, your one-stop shop to access the Paris Region life sciences' ecosystem

COMPANY :

Medicen Paris Region is the competitiveness cluster of the Paris Region and one of Europe's largest cluster in Life Sciences and Healthcare.

Founded in 2005, it connects together all the key stakeholders (leading research institutes, SMEs, incubators, large companies and the largest European hospital network) to define the best innovation policy.

Medicen Paris Region has today around 240 members, of which 180 are innovative SMEs, and is driven by the following **core mission**:

⇒ DRIVE the economic and international development of innovative small businesses by providing a set of bespoke services.
⇒ PROMOTE networking between innovators in the Paris Region: knowing each other to work better and succeed together.
⇒ CONTRIBUTE to the emergence and achievement of innovation-boosting projects.
⇒ DEVELOP an ecosystem that is intermeshed with regional and national plans and enhances the Paris Region's attractiveness on the world stage.

KEY THERAPEUTIC ASSETS include notably: Oncology, Cardio-metabolism, Immuno-infectiology, Neuro-degenerative diseases

KEY AREAS OF TECHNOLOGY :

Representing the key strengths of the region, the cluster is structured and is mobilizing its members around 5 key areas:

- ***In vitro* diagnostics:** biomarkers, companion diagnostics, reagents, innovating laboratory equipment
- **Diagnostic and interventional imaging systems:** imaging (bio)markers, *in vivo* guidance, therapeutic targeting
- **Regenerative Medicine and biomaterials**, including gene and cell therapies, tissue engineering
- **e-Health, ICT for health**: prevention, screening, diagnostic, monitoring and therapeutic care of pathologies
- **Translational medicine** for innovative treatments including molecular technologies such as sequencing, biomarkers, and metabolomics.

INTERNATIONAL OBJECTIVES :

- Develop strong partnerships with foreign clusters and key ecosystems
- Initiate innovative collaborative R&D projects
- Foster international development of our SMEs

Help foreign companies develop their activities/trials in the Paris Region

MEDICEN PARIS REGION
3-5 Impasse Reille
75014 Paris
France

www.medicen.org

Olivier FONTAINE
European and International Affairs

☎ + 33 (0)1 79 68 10 99

+33 (0) 6.73.16.78.18

✉ ofontaine@medicen.org

Affiliated to the following cluster:



Informations et contacts :
www.businessfrance.fr
info@businessfrance.fr

Business France

Business France is the national agency supporting the international development of the French economy, responsible for fostering export growth by French businesses, as well as promoting and facilitating international investment in France. It promotes French companies, business image and nationwide attractiveness as an investment location, and also runs the V.I.E (Volunteership for International Experience) program. Founded on January 1, 2015 through a merger between UBI-FRANCE and the Invest in France Agency, Business France has 1,500 personnel, both in France and in 70 countries throughout the world, who work with a network of public and private sector partners.

Business France Cluster Service

Business France signed an Convention with the Directorate General for Enterprises to accompany the clusters and their members in their international development. The objective is to facilitate technology partnerships: joint development of processes, products and services with foreign players, companies, R&D centers, etc.

Business France Marseille (Branch Office): Espace Gaymard - 2 place d'Arvieux - 13002 MARSEILLE
Business France - Head Office: 71-77 boulevard Saint Jacques - 75014 PARIS
Website: www.businessfrance.fr

Contacts:

Monique ARRIBET - Project Manager - Competitiveness Clusters and Technological Partnership Department - Health Biotechnology
✉ monique.arribet@businessfrance.fr - ☎ +33 (0)4 96 17 25 38

Jean-Charles JUBENOT - Assistant / Project Manager - Competitiveness Clusters and Technological Partnership Department
✉ jean-charles.jubenot@businessfrance.fr - ☎ +33 (0)4 96 17 25 82

Business France North America - Boston office

Business France supports French companies in their business development on the american market. Main operational activities include providing information and assistance to businesses seeking to export, promoting French companies and technologies (trade shows, etc...), helping businesses setting up in the United States of America , etc.

Business France SWEDEN - Stockholm office
Storgatan 11 - 11444 STOCKHOLM
☎ + 46(0) 85 45 89 153
E-mail: stockholm@businessfrance.fr
Website: http://www.youbuyfrance.com/se/

Contact:

Pia LEVIN - Senior Trade Advisor
☎ + 46(0)8 54 589 155 - ✉ pia.levin@businessfrance.fr

The Directorate General for Enterprises (DGE)

Under the authority of the Minister for the Economy, Industry and Digital Affairs, the DGE is tasked with developing and implementing government policy for industry, digital economy, tourism, commerce, craft industries and trade and services, to promote business start-ups, growth, innovation and competitiveness for companies of all sizes in France and abroad.

DGE - Service de la Compétitivité et du Développement des PME
61 boulevard Vincent Auriol - 757034 PARIS Cedex 13 - France

Website: http://www.entreprises.gouv.fr/la-dge/missions

Contact:
Marie-Claude SIMONI - Project Manager - International Partnerships Unit
☎ +33 (0)1 44 97 28 11 - ✉ marie-claude.simoni@finances.gouv.fr

BUSINESSFRANCE